Dogwood Therapeutics, Inc. Operating Lease Cost
Dogwood Therapeutics, Inc. (DWTX) reported Operating Lease Cost of $16.69 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-14
- Dogwood Therapeutics, Inc. operating lease, cost for the quarter ending 2026-06-30 was $16.69K, a 0.02% decline year-over-year.
- Dogwood Therapeutics, Inc. operating lease, cost for the quarter ending 2026-03-31 was $16.84K, a 4.63% increase year-over-year.
- Dogwood Therapeutics, Inc. operating lease, cost for the quarter ending 2025-12-31 was $16.56K.
- Dogwood Therapeutics, Inc. operating lease, cost for the quarter ending 2025-09-30 was $16.77K.
- Dogwood Therapeutics, Inc. operating lease, cost for fiscal 2025 was $66.11K, a 272.02% increase from fiscal 2024.
- Dogwood Therapeutics, Inc. operating lease, cost for fiscal 2024 was $17.77K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.69K 10-Q · filed 2026-08-14 | $33.53K 10-Q · filed 2026-08-14 | $50.09K derived: sum of 3 quarters · filed 2026-08-14 | $66.86K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $16.84K 10-Q · filed 2026-05-15 | $33.40K derived: sum of 2 quarters · filed 2026-05-15 | $50.17K derived: sum of 3 quarters · filed 2026-05-15 | $66.86K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $16.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $33.33K derived: sum of 2 quarters · filed 2026-03-18 | $50.02K derived: sum of 3 quarters · filed 2026-08-14 | $66.11K 10-K · filed 2026-03-18 |
| 2025-09-30 | $16.77K 10-Q · filed 2025-11-07 | $33.46K derived: sum of 2 quarters · filed 2026-08-14 | $49.55K 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $16.69K 10-Q · filed 2026-08-14 | $32.78K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $16.09K 10-Q · filed 2026-05-15 | |||
| 2024-12-31 | $17.77K 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |